Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016-08-20
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.
Related Questions
And how should we compare checkpoint inhibitors? Given the FDA approval of atezolizumab and nivolumab as second-line agents for metastatic urothe...
New answer by Medical Oncologist at University of Washington School of Medicine (March 31, 2017)
Great question, currently only atezolizumab and nivolumab are FDA-approved in this setting. Overall, there are several parameters to take into account (by the way, I suggest a...